Risen Pharma Announces Initiation of Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s DiseaseSHANGHAI, May 19, 2026 (GLOBE NEWSWIRE) -- Risen Pharma, a clinical-stage biotech company focusing on the development and commercialization of high-need, patient-accessible therapeutics, today announced the initiation of a Phase 2 clinical study in China of RP902, an oral small-molecule drug developed to address significant unmet medical needs in patients with Alzheimer's disease.
Amplexd Therapeutics Initiates Phase 2 Clinical Trial of Investigational EGCg-Based HPV TherapyGAITHERSBURG, Md., May 19, 2026 (GLOBE NEWSWIRE) -- Amplexd Therapeutics, Inc. (“Amplexd”), a U.S.-based clinical-stage biotechnology company focused on women’s health and underserved therapeutic areas, today announced authorization from the Hong Kong Department of Health to initiate a Phase 2 clinical trial evaluating its novel EGCg-based investigational therapy for precancerous cervical lesions associated with high-risk human papillomavirus (hr-HPV).
Syntec Optics (Nasdaq: OPTX) Makes Deep Tech Deliveries for Next Gen Defense, Space, and Hyperscale AIROCHESTER, NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Syntec Optics Holdings, Inc. (Nasdaq: OPTX) (“Syntec” or the “Company”), a leading provider of products for defense tech, space tech, and other vibrant end markets, today announced a series of pioneering product delivery milestones that have taken nearly 12 months to achieve. The Company has successfully manufactured and delivered next-generation products operating at the leading edge and frontier, achieving high accuracy in nanoscale irregularity across highly complex defense, space, and Artificial Intelligence platforms.
GDEV announces results for the first quarter of 2026LIMASSOL, Cyprus, May 19, 2026 (GLOBE NEWSWIRE) -- GDEV Inc. (
NASDAQ: GDEV), an international gaming and entertainment company (“GDEV” or the “Company”) released its unaudited financial and operational results for the three-month period ended March 31, 2026.
SecureAuth Launches Agentic Authority Platform and Names Mark van Oppen Chief Revenue Officer to Lead the Next Era of Identity Security in the Age of AIZero-trust security for AI agents authorizes every action in real time against full request context, with industry veteran Mark van Oppen joining as CRO to drive enterprise growth
Hudson InterXchange Continues 60 Hudson Expansion with Second 1MW Data Hall and Roadmap Beyond 10 MWNew High-Density Capacity Delivers Scarce Power and Contiguous Space for AI, Cloud, Financial Services and Network-Driven Workloads in New York City
Fluent, Inc. Selected as Commerce Media Partner for BackpackSM Media by SalliePartnership Powers Monetization and Advertiser Performance Across Predictive Life-Stage Intelligence
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in a fireside chat at the Jefferies Global Healthcare Conference 2026 on June 3 at 9:55 a.m. ET in New York.
Advanced Magnet Lab (AML) Awarded $2 Million Defense Logistics Agency (DLA) Contract to Qualify Innovative, 100% U.S.-Made High-Grade Sintered NdFeB Permanent Magnets for DefenseAward Advances AML's Multi-Phase Partnership with the U.S. Government and Further Establishes the Company's PM-Wire™ Manufacturing Process as a Backbone of Domestic Permanent Magnet Production
Phoenix Lighting Announces Completion of Acquisition of Rig-A-LiteTransaction Expands Phoenix Lighting's Industrial and Commercial Lighting Portfolio and Strengthens Its Position as a Leading Manufacturer of Specification-Grade Lighting Solutions
UneeQ Unveils AI Buddy at the Gartner CSO & Sales Leader Conference 2026The first coaching capability in the market to deliver face-to-face, spoken coaching from a digital human, turning every practice session into an immediate and personal coaching conversation
Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1Milestone advances commercial and manufacturing readiness ahead of anticipated pivotal study scale-up
Open Source Stays Open: Percona Sponsors pgBackRest to Keep PostgreSQL Backups RunningRALEIGH, N.C., May 19, 2026 (GLOBE NEWSWIRE) -- When pgBackRest's primary maintainer announced he would step away due to a lack of sustainable funding, Percona didn't wait. The open source database company today announced it has joined a group of companies to sponsor pgBackRest, one of PostgreSQL's most widely used backup and recovery tools, restoring active development and giving users a clear path forward.
Shufti Recognised as Dual Leader in Liminal's 2026 Age Verification and Age Estimation Indexes, with Exceptional Ratings Across Both BenchmarksLiminal’s independent buyer-led research positions Shufti among the highest-scoring vendors on Product Execution, Strategy, and Market Presence, citing its risk-based age assurance, sub-second inference, and privacy-preserving on-device capabilities
Stellantis MarketCenter to Launch Point Predictive’s BorrowerCheck™ with Driver’s License Scan Across U.S. Dealer NetworkMore than 2,600 Chrysler, Dodge, Jeep, Ram, FIAT, and Alfa Romeo dealerships will gain access to AI-powered fraud prevention and real-time identity verification directly inside the Stellantis MarketCenter platform
TON Strategy Company Highlights Launch of Acton Developer Toolchain for the TON EcosystemLAS VEGAS, May 19, 2026 (GLOBE NEWSWIRE) -- TON Strategy Company (“TON Strategy” or the “Company”) (Nasdaq: TONX), a digital asset treasury company dedicated to supporting the TON ecosystem, today spotlighted the recent introduction of Acton, a new integrated developer toolchain for The Open Network (“TON”). Acton is designed to simplify how developers build, test, debug, deploy and audit TON-based smart contract applications and is intended to support the next generation of AI-native and agentic applications on the TON blockchain.
Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed PlatformVeteran physician, medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience, mobility technologies, and metabolic disease
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and DevelopmentVeteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and company building
Rocket Doctor Enters into North Star AgreementVancouver, BC, May 19, 2026 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI”) announces that, subject to regulatory approval, it has entered into an agreement dated May 15, 2026 with North Star Investor Relations Inc. (“North Star”) pursuant to which the Company has engaged the services of North Star to provide investor relations and marketing services, beginning on May 15, 2026.
Sunrun Earns Four 2026 Buyer’s Choice Awards from ConsumerAffairs, Including Best Customer ServiceThe annual Buyer's Choice Awards recognize top-rated brands across key consumer categories, based on in-depth analysis of customer reviews published on ConsumerAffairs.com
Venture For ClimateTech Announces Cohort 6 of High-Impact Startups Advancing Climate Innovation10 Companies Selected to Receive Up to $50,000 Each and Accelerate Commercialization of Climate Technologies
Jenfi Surpasses US$100 Million in SME Financing Across Southeast AsiaSINGAPORE, May 19, 2026 (GLOBE NEWSWIRE) -- Jenfi, a Southeast Asia-focused SME credit platform, today announced that it has surpassed US$100 million in cumulative financing originations across the region, marking a significant milestone in the company’s continued expansion across Singapore and Vietnam.
Hudbay Publishes its 2025 Annual Report “the Gold Standard in Copper”TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Hudbay Minerals Inc. (“Hudbay” or the “Company”) (TSX, NYSE: HBM) today announced the release of its 2025 annual report (“Annual Report”), which provides updates on key business, financial and sustainability initiatives and accomplishments from last year. The sustainability disclosure in the Annual Report is aligned with recognized global reporting standards.
Globavend Welcomes Pictureworks CEO to Lead Its AI-Driven Entertainment BusinessPERTH, Australia, May 19, 2026 (GLOBE NEWSWIRE) -- via IBN -- Globavend Holdings Limited (
NASDAQ: GVH) (“Globavend” or the “Company”), an emerging e-commerce logistics provider and digital entertainment company, today announced the appointment of Fuk Yan Tse, known as Sharon Tse (“Ms. Tse” or “Sharon”), as Chief Executive Officer of Loomi Group, the operating arm of the Company’s digital entertainment business. This newly created position follows the Company’s transformational move into the digital entertainment industry. Ms. Tse will oversee the operations and strategy of the Company’s digital entertainment business following the completion of the acquisition of Loomi Entertainment Group Limited and its subsidiaries (“Loomi Group”).
Onconetix, Inc. Announces 1-for-10 Reverse Stock SplitCINCINNATI, Ohio, May 19, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (
NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for oncology, today announced that its Board of Directors (the “Board of Directors” or “Board”) has approved a 1-for-10 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on May 21, 2026.
Magna Awarded Driver and Occupant Monitoring System Program With European OEMAURORA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- Magna has been awarded a Driver and Occupant Monitoring System (DMS/OMS) program with a European OEM. The program marks a significant expansion of Magna’s DMS/OMS across global vehicle platforms and positions the company’s mirror-integrated system as a foundational element within next-generation vehicle architecture.
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship AwardSCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (
NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the recipients of the second annual CG-SUO-CTC NMIBC Research Fellowship designed to support the development of outstanding clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). They include:
ITM to Announce Dosimetry Data from the Phase 3 COMPETE Trial at SNMMI 2026 and Host Satellite SymposiumGarching / Munich, May 19, 2026 –– ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that dosimetry data from its Phase 3 COMPETE trial will be provided in a poster presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, held from May 30 - June 2, 2026 in Los Angeles, California. ITM will also host a satellite symposium on the evolution of SSTR-targeted radiopharmaceutical therapy.Poster Presentation DetailsTitle: Accurate single-time-point dosimetry of [177Lu]Lu-edotreotide using non-linear mixed-effects modeling: results from the COMPETE Phase 3 trialDisplay Date and Location: May 31 – June 2 at the SNMMI Science PavilionSatellite Symposium DetailsTitle: ITM Dinner Symposium – The Evolution of SSTR‑Targeted Therapy – from Agonists to Antagonists and Emerging RadionuclidesObjective: Discuss the evolution of SSTR‑targeted radiopharmaceutical therapy; spanning early approaches, current ¹⁷⁷Lu agonist therapies to next‑generation ligand biology and emerging radionuclides – linking today’s clinical practice with future therapeutic directionsSpeaker: Dr. Julia Fricke, MD, Clinic for Radiology and Nuclear Medicine at the University Hospital Basel, SwitzerlandDate: May 31, 2026, 6:30 PM - 7:30 PM PTLocation: Petree Hall C, LA Convention Center, Los Angeles, CADuring the conference, ITM will exhibit its innovative isotope portfolio, including Lutetium-177, Actinium-225 and Terbium-161. Attendees will have the opportunity to learn more about the company’s innovative radiopharmaceutical pipeline and its capabilities in the manufacturing and supply of radioisotopes at booth #1523.About the COMPETE TrialThe COMPETE trial (NCT03049189) evaluated 177Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic investigational agent compared to everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This trial met its primary endpoint, with 177Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus. 177Lu-edotreotide is an investigational product pending review by the U.S. Food and Drug Administration (FDA) and is not approved by any regulatory authority for the safety and/or efficacy of any intended use. It is also being evaluated in COMPOSE (NCT04919226), a Phase 3 study in patients with well-differentiated, aggressive Grade 2 or Grade 3, somatostatin receptor (SSTR)-positive GEP-NETs.About ITM Isotope Technologies Munich SEITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.comITM ContactCorporate CommunicationsKathleen Noonan/Julia WestermeirPhone: +49 89 329 8986 1500Email: communications@itm-radiopharma.comInvestor RelationsBen OrzelekPhone: +49 89 329 8986 1009Email: investors@itm-radiopharma.com
D-Orbit and ELECTRA AI Sign MoU to Bring AI Battery Intelligence to Space~ Real-time on the satellite. Analytics across the fleet. Same brain. New frontier. ~
Exyn Defense Subsidiary Range Advances USSOCOM Evaluation Pathway for Autonomous SystemsPHILADELPHIA, PA, May 19, 2026 (GLOBE NEWSWIRE) -- Exyn Technologies (“Exyn” or the “Company”) (NASDAQ: EXYN, EXYNW), a leader in autonomous mapping and perception-driven navigation for complex, GPS-denied environments, today announced it executed a Vendor Loan Agreement with the United States Special Operations Command (USSOCOM) to establish a pathway for future adoption of Range’s autonomy systems. Range also entered an agreement with Asylon Robotics to support the U.S. Air Force Warner Robins Air Logistics Complex, applying ExynAI to autonomous inspection and operational efficiency programs within the Organic Industrial Base (OIB).
LaunchDarkly Brings Runtime Control to the Agent EraNew solution gives engineering teams instantaneous control over AI agent behavior in production without redeployment
XRP POWER Launches Global App with AI-Powered Smart System, Ushering in a New Era of More Stable ReturnsWith the continuous development of artificial intelligence technology and the new energy industry, the digital finance sector is undergoing significant changes. Compared to past participation methods that relied on frequent trading and complex operations, more and more users are focusing on a more stable, intelligent, and efficient digital service experience. The integration of AI automation systems with the green new energy ecosystem is gradually becoming a new direction for industry development.
Integer Technologies and Cellula Robotics Partner to Advance Adaptive Mission Assurance for Long-Range Multi-Vehicle Undersea OperationsThe collaboration will explore how Integer’s DIGIT COMMAND can layer onto Cellula’s Nexus mission control software through a back-seat driver architecture, supporting adaptive tasking, system awareness and operator confidence in communications-constrained environments
BrainHQ Awarded the Gold: Earns Trusted Digital Badge from APA Labs, a unit of American Psychological Association Services, Inc.SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- BrainHQ, the premier brain-training platform developed by Posit Science, has earned the Gold Badge from APA Labs – a unit of APA Services, Inc., the companion professional association of the American Psychological Association (APA). This elite status recognizes BrainHQ for excellence in clinical rigor and establishes it as a trusted, evidence-based solution in the crowded and largely unregulated digital mental health marketplace. BrainHQ is currently the third app to earn the Gold Digital Badge, and is the first app focused on brain training for cognitive enhancement.
Rezolve Ai Solves the 26% AI Distortion Crisis Stalling Global Retail; Peer-Reviewed Research Validates Near-Perfect AccuracyNew Research Showing 26.5% AI Product-Review Distortion and 60% Hallucination Rates Proves Commerce Needs Verified Intelligence
Science 37 and Tufts CSDD Publish Landmark Study on Direct-to-Patient Clinical Trial Site Performance, Outperforming Industry BenchmarksMORRISVILLE, N.C., May 19, 2026 (GLOBE NEWSWIRE) -- Science 37 today announced the publication of a new analysis in Applied Clinical Trials in collaboration with the Tufts Center for the Study of Drug Development (Tufts CSDD). The study evaluates the performance of Science 37’s Direct-to-Patient (DTP) Site against established industry benchmarks, providing an empirical assessment of how the DTP site model, when added along with traditional sites, can improve study performance.
Arctera and Enterprise Vault Expand Leadership Team with New Sales Leaders to Drive Strategic GrowthSAN RAMON, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Arctera and Enterprise Vault, both business units of Cloud Software Group, today announced the appointment of three new sales leaders to support continued growth across its enterprise compliance and governance portfolios. The appointments include Jeff Thomas as Global Sales Leader for Enterprise Vault, along with Chris Hartley as Americas Sales Leader for Arctera and Brenda Sheahan as International Sales Leader for Arctera.
Mattr Reports Voting Results from Annual MeetingTORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Mattr Corp. (“Mattr” or the “Company”) (TSX: MATR) announced today in accordance with Toronto Stock Exchange requirements, the voting results from its Annual Meeting held May 14, 2026 in Toronto, Ontario.
Compass Lexecon Expands Antitrust Expertise With Addition of Two AffiliatesWASHINGTON, May 19, 2026 (GLOBE NEWSWIRE) -- Compass Lexecon, a subsidiary of FTI Consulting, Inc. (
NYSE: FCN), today announced that Anja Lambrecht, a Professor of Marketing at London Business School, and Matthew Notowidigdo, the David McDaniel Keller Professor of Economics at the University of Chicago Booth School of Business, have affiliated with the firm.
Creative Realities to Participate in Upcoming Craig-Hallum ConferenceLOUISVILLE, Ky., May 19, 2026 (GLOBE NEWSWIRE) -- Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (
NASDAQ: CREX), a leading provider of digital signage, media and AdTech solutions, today announced that it will participate in the 23rd Annual Craig-Hallum Institutional Investor Conference in Minneapolis on Thursday, May 28, at the Depot Renaissance Hotel. The day will consist of one-on-one meetings with management, and institutional investors can contact Craig-Hallum directly to set up time with the Company.
Global Indemnity Group, LLC Announces Appointment of Michele Colucci to the Board of DirectorsWILMINGTON, Del., May 19, 2026 (GLOBE NEWSWIRE) -- Global Indemnity Group, LLC (
NASDAQ: GBLI) (“GBLI”) today announced the appointment of Michele Colucci to its Board of Directors, effective May 18, 2026.
RenX Advances Microtec Commercialization with Customer Sample Run in GermanyMIAMI, FL, May 19, 2026 (GLOBE NEWSWIRE) -- RenX Enterprises Corp. (
NASDAQ: RENX) (“RenX” or the “Company”) today announced three operational updates supporting the planned deployment of the Microtec UTM 1200 Turbo Mill at its Myakka City, Florida facility: (1) the initiation of an customer sample run at MTDH Germany GmbH (“Microtec”); (2) the acquisition of a spare parts package bundled with the mill and (3) the funding of contract deposits to the Company’s site commissioning and electrical infrastructure partners.
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy– Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA –
SiTime Corporation Announces Proposed Convertible Senior Notes OfferingSANTA CLARA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- SiTime Corporation (“SiTime”) (
NASDAQ: SITM), the Precision Timing company, today announced its intent to offer, subject to market conditions and other factors, $1.1 billion aggregate principal amount of Convertible Senior Notes due in 2031 (the “Notes”) in an underwritten offering (the “Offering”). SiTime also intends to grant the underwriters of the Notes a right to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $150 million aggregate principal amount of Notes, solely to cover over-allotments, if any.
CRB Horizons Report Reveals Food and Beverage Manufacturers Confront Aging Facilities, Labor Shortages, and Regulatory Pressure Amid Rising Safety RisksSurvey of 300 food and beverage leaders shows rising investment in automation and traceability, yet a persistent gap remains between strategy and execution
Antalpha Reports First Quarter 2026 ResultsSINGAPORE, May 19, 2026 (GLOBE NEWSWIRE) -- Antalpha Platform Holding Company (
NASDAQ: ANTA) ("Antalpha" or the "Company") today announced its unaudited financial results for the first quarter ended March 31, 2026.
Vanqua Bio to Present Positive Biomarker Data from Ongoing Phase 1b Study at Upcoming Medical ConferencesCHICAGO, May 19, 2026 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present interim data from its Phase 1b study at World Parkinson’s Congress and the GBA1 Meeting 2026, both taking place in Phoenix, AZ May 22nd – May 27th.
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple SclerosisBOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces updated clinical data from its ongoing Expanded Access ("EA") Program evaluating intranasal foralumab in 14 patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The data, updated from March 2025 to as of March 2026, demonstrate that intranasal foralumab continues to be extremely well tolerated over extended treatment durations. Patients showed encouraging trends in stabilization of disability as measured by the Expanded Disability Status Scale (EDSS) and meaningful improvements in fatigue as measured by the Modified Fatigue Impact Scale (MFIS).
Osisko Development Appoints Vice President, Sustainable DevelopmentMONTREAL, May 19, 2026 (GLOBE NEWSWIRE) -- Osisko Development Corp. (NYSE: ODV, TSXV: ODV) ("Osisko Development" or the "Company") is pleased to announce the appointment of Mr. Greg Perrins as Vice President, Sustainable Development, effective May 18, 2026.
Reminder: Garrett Motion to Hold Technology and Investor Day on Wednesday May 20, 2026PLYMOUTH, Mich. and ROLLE, Switzerland, May 19, 2026 (GLOBE NEWSWIRE) -- Garrett Motion Inc. (Nasdaq: GTX), a global leader in differentiated turbocharging and electrification technologies, extends a reminder to investors, analysts, and other stakeholders to join its 2026 Technology and Investor Day on May 20, 2026.
Blossom Gold Files Notice of Intent with the BLM to Initiate Exploration Drilling on the Kamma Claims West of the Rosebud ProjectTORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Blossom Gold Inc. (“Blossom” or the “Company”) (TSX: BGAU) is pleased to announce that the Company, through its wholly owned subsidiary Blossom Gold (Nevada) Inc., has filed a Notice of Intent ("NOI") with the U.S. Bureau of Land Management ("BLM") for exploration activities on the Company's Kamma Claims west of the Rosebud Project ("Rosebud" or the "Project") in Pershing County, Nevada. The BLM review and approval process is expected to take between 15 and 30 days.
Troilus Expands High-Grade West Rim Discovery with 2.92 g/t AuEQ Over 19 m Outside Current Resource and Within 200 Metres of Reserve PitMONTREAL, May 19, 2026 (GLOBE NEWSWIRE) -- Troilus Mining Corp. (“Troilus” or the “Company”, TSX: TLG; OTCQX: CHXMF; FSE: CM5R) is pleased to announce the first batch of results from the West Rim Zone (“West Rim”) as part of its ongoing 2026 Exploration Program (see March 31, 2026 press release) at its copper-gold Troilus Project located in northcentral Quebec, Canada.
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhDLONDON and NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced the expansion of their Scientific Advisory Board (SAB) with the appointment of Marta Sacchetti, MD, PhD. This appointment further enhances the Company’s global scientific network with premier European specialists.
New Vertex Research Highlights Rising Revenue Risk from IT, Tax, and Finance MisalignmentOnly 12% of organizations globally have fully integrated tax technology, even as real-time compliance becomes business critical
Mantel and Wood Announce MOU to Scale High-Temperature Carbon CaptureWood named preferred fired-equipment partner as first commercial project advances in Western Canada
Ambow Education Holding Ltd. (NYSE American: AMBO) Launches HybriU Collaboration Board, Bringing One-Scan Real-Time Collaboration to Meetings, Classrooms, Workshops, and Live EventsNew AI-Powered Phygital (Physical + Digital) Tool Lets Participants Join a Shared Interactive Whiteboard via a Single QR Code Scan, With Real-Time Support for PDFs, PowerPoint, Images, Sketches, and Drawings
OTC Markets Group Welcomes Cambria Gold Mines Inc. to OTCQXNEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Cambria Gold Mines Inc. (TSX-V: CAMB; OTCQX: CAMVF), a Canadian mining company, has qualified to trade on the OTCQX® Best Market. Cambria Gold Mines Inc. upgraded to OTCQX from Pink Limited™ Market.
Consumers Accelerate Shift Toward DIY Vehicle Maintenance Amid Economic PressuresNewly launched Circana insights reveal growth in automotive hand tools, signaling more DIY tasks to come
EuroPCR 2026: Elixir Medical’s DynamX® Bioadaptor Demonstrates Significantly Lower Event Rates Than Drug-Eluting StentEuroPCR 2026: Elixir Medical’s DynamX® Bioadaptor Demonstrates Significantly Lower Event Rates Than Drug-Eluting Stent in Long-Term Follow-Up, Including Reduction in Cardiovascular Death
Blossom Gold Completes Drilling of Metallurgical Core Holes and Begins Delivering Metallurgical Samples to Kappes, Cassiday & Associates to Initiate Metallurgical Testing on Rosebud MineralizationTORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Blossom Gold Inc. (“Blossom” or the “Company”) (TSX: BGAU) is pleased to announce that all initially planned metallurgical drill holes at its Rosebud Project in Pershing County, Nevada have been completed. Blossom and Kappes, Cassiday & Associates ("KCA") are now coordinating on the selection of sample intervals to initiate metallurgical test work with the first of several core shipments having arrived at KCA for preparation and initiation of test work.
Planet 13 Receives OMMU Approval for Florida BHO Extraction FacilityLAS VEGAS, May 19, 2026 (GLOBE NEWSWIRE) -- Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNH) (“Planet 13” or the “Company”), a leading vertically-integrated multi-state cannabis company, today announced that its Florida operations have received approval from the Florida Office of Medical Marijuana Use for its BHO extraction facility. The approval completes the final major infrastructure investment in Planet 13 Florida's operational buildout and enables the Company to serve Florida's full concentrate category for the first time.
Parsons Celebrates the Opening of D Line Subway Extension Section 1CHANTILLY, Va., May 19, 2026 (GLOBE NEWSWIRE) -- Parsons Corporation (
NYSE: PSN) announced today that the Los Angeles County Transportation Authority (Metro) has opened the D Line Subway Extension Section 1 project. The D Line Extension project is being built in three sections and will ultimately extend the transit system westward for about nine miles under Wilshire Boulevard. Section 1 includes the design and construction of 3.9 miles of subway from the current terminus at Wilshire/Western in the city of Los Angeles to the city of Beverly Hills with three new underground stations at La Brea, Fairfax, and La Cienega. Parsons served as lead designer for Section 1 and performed design management and final design.
Avance Clinical to Showcase Oncology Leadership at ASCO Annual Meeting 2026WAKE FOREST, N.C., May 19, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, a specialist global Contract Research Organization (CRO) focused on accelerating clinical development for biotechnology companies, will attend the ASCO Annual Meeting 2026, held 29 May – 2 June 2026 in Chicago, Illinois, exhibiting at Booth #37153.
Lindy Academy Expands On-Demand Training ProgrammeAccredited by AVIXA, latest module highlights collaboration and connectivity workflows needed for professional AV environments
Natural Alternatives International, Inc. Announces 2026 Q3 and YTD ResultsCARLSBAD, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $4.3 million, or $0.72 per diluted share, on net sales of $35.5 million for the third quarter of fiscal year 2026 compared to a net loss of $2.2 million, or $0.37 per diluted share, in the third quarter of the prior fiscal year.
